![Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Treatment Recommendations for Psoriatic Arthritis 2015 - ACR Meeting Abstracts Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Treatment Recommendations for Psoriatic Arthritis 2015 - ACR Meeting Abstracts](https://acrabstracts.org/wp-content/uploads/2015/09/Paper_54362_abstract_71746_0.jpg)
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Treatment Recommendations for Psoriatic Arthritis 2015 - ACR Meeting Abstracts
![Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Guidelines Pocket Guides & Apps - Guideline Central Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Guidelines Pocket Guides & Apps - Guideline Central](https://www.guidelinecentral.com/wp-content/uploads/2017/11/GRAPPA-PsA-v3a-cover-800px.png)
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Guidelines Pocket Guides & Apps - Guideline Central
![Figure 1. | Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice | The Journal of Rheumatology Figure 1. | Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice | The Journal of Rheumatology](https://www.jrheum.org/content/44/4/519/F1.large.jpg)
Figure 1. | Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice | The Journal of Rheumatology
![Psoriatic Arthritis - Musculoskeletal and Connective Tissue Disorders - Merck Manuals Professional Edition Psoriatic Arthritis - Musculoskeletal and Connective Tissue Disorders - Merck Manuals Professional Edition](https://www.merckmanuals.com/-/media/manual/professional/images/p/s/o/psoriatic-arthritis-1-yaseen-sized.jpg?thn=0&sc_lang=en)
Psoriatic Arthritis - Musculoskeletal and Connective Tissue Disorders - Merck Manuals Professional Edition
![Figure 4. | Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice | The Journal of Rheumatology Figure 4. | Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice | The Journal of Rheumatology](https://www.jrheum.org/content/44/4/519/F4.large.jpg)
Figure 4. | Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice | The Journal of Rheumatology
![Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021 | Nature Reviews Rheumatology Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021 | Nature Reviews Rheumatology](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41584-022-00798-0/MediaObjects/41584_2022_798_Fig2_HTML.png)
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021 | Nature Reviews Rheumatology
Arthritis Society Canada - In recognition of National Psoriatic Arthritis Day, we've developed this patient journey flow chart to help you navigate your way if you've just been diagnosed with PsA. Click
![Brazilian Society of Rheumatology 2020 guidelines for psoriatic arthritis | Advances in Rheumatology | Full Text Brazilian Society of Rheumatology 2020 guidelines for psoriatic arthritis | Advances in Rheumatology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs42358-021-00219-y/MediaObjects/42358_2021_219_Fig1_HTML.png)
Brazilian Society of Rheumatology 2020 guidelines for psoriatic arthritis | Advances in Rheumatology | Full Text
![Mitigation of disease- and treatment-related risks in patients with psoriatic arthritis | Arthritis Research & Therapy | Full Text Mitigation of disease- and treatment-related risks in patients with psoriatic arthritis | Arthritis Research & Therapy | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13075-017-1265-5/MediaObjects/13075_2017_1265_Fig1_HTML.gif)
Mitigation of disease- and treatment-related risks in patients with psoriatic arthritis | Arthritis Research & Therapy | Full Text
![Application of the GRAPPA Psoriatic Arthritis Treatment Recommendations in Clinical Practice | SpringerLink Application of the GRAPPA Psoriatic Arthritis Treatment Recommendations in Clinical Practice | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs11926-010-0109-y/MediaObjects/11926_2010_109_Fig1_HTML.gif)
Application of the GRAPPA Psoriatic Arthritis Treatment Recommendations in Clinical Practice | SpringerLink
![Optimising psoriatic arthritis therapy with immunological methods to increase standard evaluation: the protocol of an open-label multicentre, parallel-group, two-arm randomised controlled study evaluation precision medicine approach in the treatment of ... Optimising psoriatic arthritis therapy with immunological methods to increase standard evaluation: the protocol of an open-label multicentre, parallel-group, two-arm randomised controlled study evaluation precision medicine approach in the treatment of ...](https://bmjopen.bmj.com/content/bmjopen/13/9/e078539/F1.large.jpg)
Optimising psoriatic arthritis therapy with immunological methods to increase standard evaluation: the protocol of an open-label multicentre, parallel-group, two-arm randomised controlled study evaluation precision medicine approach in the treatment of ...
![Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE) - The Lancet Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE) - The Lancet](https://www.thelancet.com/cms/asset/ee8534ec-8247-43fa-8b1b-37716bddacd3/gr1.jpg)
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE) - The Lancet
![Advancing the Treatment of Psoriatic Arthritis: Focus on the IL-23 Pathway - European Medical Journal Advancing the Treatment of Psoriatic Arthritis: Focus on the IL-23 Pathway - European Medical Journal](https://www.emjreviews.com/wp-content/uploads/2020/07/Figure-1-The-cytokine-environment.png)
Advancing the Treatment of Psoriatic Arthritis: Focus on the IL-23 Pathway - European Medical Journal
![2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis - Jasvinder A. Singh, Gordon Guyatt, Alexis Ogdie, Dafna D. Gladman, Chad Deal, Atul Deodhar, Maureen Dubreuil, Jonathan 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis - Jasvinder A. Singh, Gordon Guyatt, Alexis Ogdie, Dafna D. Gladman, Chad Deal, Atul Deodhar, Maureen Dubreuil, Jonathan](https://journals.sagepub.com/cms/10.1177/2475530318812244/asset/images/large/10.1177_2475530318812244-fig3.jpeg)
2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis - Jasvinder A. Singh, Gordon Guyatt, Alexis Ogdie, Dafna D. Gladman, Chad Deal, Atul Deodhar, Maureen Dubreuil, Jonathan
![New Novartis two-year data for investigational secukinumab revealed no progression in joint damage in 84% of psoriatic arthritis patients New Novartis two-year data for investigational secukinumab revealed no progression in joint damage in 84% of psoriatic arthritis patients](http://photos.newswire.ca/images/20151110_C6083_PHOTO_EN_541039.jpg)
New Novartis two-year data for investigational secukinumab revealed no progression in joint damage in 84% of psoriatic arthritis patients
![Predicting response to therapy among patients with psoriatic arthritis - results from the British Society of Rheumatology Psoriatic Arthritis Register (BSR-PsA) - GRAPPA Network Predicting response to therapy among patients with psoriatic arthritis - results from the British Society of Rheumatology Psoriatic Arthritis Register (BSR-PsA) - GRAPPA Network](https://www.grappanetwork.org/wp-content/uploads/2023/07/GRAPPA-Poster-A0-landscape-S.Lembke_v03-pdf.webp)
Predicting response to therapy among patients with psoriatic arthritis - results from the British Society of Rheumatology Psoriatic Arthritis Register (BSR-PsA) - GRAPPA Network
![Recommendations for psoriatic arthritis management: A joint position paper of the Taiwan Rheumatology Association and the Taiwanese Association for Psoriasis and Skin Immunology - ScienceDirect Recommendations for psoriatic arthritis management: A joint position paper of the Taiwan Rheumatology Association and the Taiwanese Association for Psoriasis and Skin Immunology - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0929664620304009-gr1.jpg)
Recommendations for psoriatic arthritis management: A joint position paper of the Taiwan Rheumatology Association and the Taiwanese Association for Psoriasis and Skin Immunology - ScienceDirect
![Psoriatic arthritis: the role of the nonphysician clinician in the diagnosis and treatment of patients with psoriasis | Drugs & Therapy Perspectives Psoriatic arthritis: the role of the nonphysician clinician in the diagnosis and treatment of patients with psoriasis | Drugs & Therapy Perspectives](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40267-021-00814-5/MediaObjects/40267_2021_814_Fig1_HTML.jpg)
Psoriatic arthritis: the role of the nonphysician clinician in the diagnosis and treatment of patients with psoriasis | Drugs & Therapy Perspectives
![IJMS | Free Full-Text | The Risk of Systemic Diseases in Those with Psoriasis and Psoriatic Arthritis: From Mechanisms to Clinic IJMS | Free Full-Text | The Risk of Systemic Diseases in Those with Psoriasis and Psoriatic Arthritis: From Mechanisms to Clinic](https://pub.mdpi-res.com/ijms/ijms-21-07041/article_deploy/html/images/ijms-21-07041-g001.png?1602311032)
IJMS | Free Full-Text | The Risk of Systemic Diseases in Those with Psoriasis and Psoriatic Arthritis: From Mechanisms to Clinic
![PDF) Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative PDF) Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative](https://i1.rgstatic.net/publication/280120891_Evidence-based_Recommendations_for_the_Management_of_Comorbidities_in_Rheumatoid_Arthritis_Psoriasis_and_Psoriatic_Arthritis_Expert_Opinion_of_the_Canadian_Dermatology-Rheumatology_Comorbidity_Initiat/links/571e76b908aefa648899a173/largepreview.png)
PDF) Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative
![Health Canada Approves AbbVie's RINVOQ® (upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Health Canada Approves AbbVie's RINVOQ® (upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis](https://mma.prnewswire.com/media/1526664/AbbVie_Canada_Health_Canada_Approves_AbbVie_s_RINVOQ___upadaciti.jpg?w=200)
Health Canada Approves AbbVie's RINVOQ® (upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
![The state of the art—psoriatic arthritis outcome assessment in clinical trials and daily practice - The Lancet Rheumatology The state of the art—psoriatic arthritis outcome assessment in clinical trials and daily practice - The Lancet Rheumatology](https://www.thelancet.com/cms/asset/104e0f86-069f-4393-b49a-4624140bd4a7/gr1.jpg)